Literature DB >> 33712403

Predictors of Depression in Men With Peyronie's Disease Seeking Evaluation.

Nahid Punjani1, Bruno Nascimento2, Carolyn Salter3, Eduardo Miranda4, Jean Terrier3, Hisanori Taniguchi3, Lawrence Jenkins3, John P Mulhall5.   

Abstract

BACKGROUND: Peyronie's disease (PD) has negative impacts on the psychosocial status of men including depression warranting clinical evaluation in up to 50% of men. AIM: To examine predictors of depression in patients with early PD seeking evaluation.
METHODS: All PD patients at a high-volume PD practice underwent screening and curvature assessment after intracavernosal injection. Complex deformity was defined as any degree of multiplanar curvature, curvature >60 degrees, or presence of hourglass deformity. Men completed the PD questionnaire (PDQ), a validated depression questionnaire (CES-D) as well as the Self-Esteem and Relationship (SEAR) questionnaire. Scores of ≥16 on CES-D were considered indicative of moderate/severe depression. Predictors of the presence of depression were defined using univariable and multivariable logistic regression. OUTCOMES: Demographic, bother and curve related predictors of depression in men with PD.
RESULTS: 408 men completed all questionnaires. Mean age was similar between depressed and nondepressed groups (57 ± 10 years overall, P = .60 between groups). Proportions of erectile dysfunction were similar between groups (P = .96). Mean PD duration was similar between groups (19 ± 35 months overall, P = .46 between groups). Mean degree of curvature was 38 ± 2 degrees in the depressed vs 33 ± 1 degrees in the nondepressed groups (P = .03). A complex deformity was seen in 64.5% in the depressed vs 61.5% in the nondepressed (P = .56). A total of 110 (27%) patients had CESD scores ≥16. 74% depressed men were in relationships compared to 84% nondepressed men (P < .01). Other characteristics including bother, pain, duration of disease, curve complexity and instability were similar between the two groups. On univariable analysis, factors protective against depression included being partnered (OR 0.42, 95%CI 0.24-0.75, P < .01) and higher total SEAR scores (OR 0.95, 95%CI 0.94-0.97, P < .01). Elevated PDQ domain scores were associated with depression (Psychologic Symptoms 1.05, 95%CI 1.02-1.10, P < .01; Pain 1.08, 95%CI 1.03-1.12, P < .01; Bother 1.11, 95% CI 1.05-1.68, P < .01) as well as baseline history of depression (OR 2.93, 95%CI 1.67-5.14, P < .001). On multivariable analysis, only total SEAR score remained protective against depression (OR 0.96, 95%CI 0.94-0.97, P < .001). CLINICAL IMPLICATIONS: Providers must recognize that men with PD seeking evaluation have meaningful rates of depression for which early recognition is necessary. STRENGTHS AND LIMITATIONS: Retrospective review of a large prospectively collected dataset from a single center of men with PD utilizing a validated screening tool for depression.
CONCLUSION: While no significant demographic, bother or curve related factors predicted depression in early PD men seeking evaluation, it remains a significant problem warranting further prospective evaluation. P. Nahid, N. Bruno, S. Carolyn, et al. Predictors of Depression in Men With Peyronie's Disease Seeking Evaluation. J Sex Med 2021;18:783-788.
Copyright © 2021 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depression; Mental health; Peyronie's disease

Mesh:

Year:  2021        PMID: 33712403      PMCID: PMC9087901          DOI: 10.1016/j.jsxm.2021.02.002

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.937


  27 in total

1.  Men and depression.

Authors:  John S Ogrodniczuk; John L Oliffe
Journal:  Can Fam Physician       Date:  2011-02       Impact factor: 3.275

Review 2.  Psychological impact of Peyronie's disease: a review.

Authors:  Christian J Nelson; John P Mulhall
Journal:  J Sex Med       Date:  2012-11-15       Impact factor: 3.802

3.  Development and validation of the Self-Esteem And Relationship (SEAR) questionnaire in erectile dysfunction.

Authors:  J C Cappelleri; S E Althof; R L Siegel; A Shpilsky; S S Bell; S Duttagupta
Journal:  Int J Impot Res       Date:  2004-02       Impact factor: 2.896

4.  The chronology of depression and distress in men with Peyronie's disease.

Authors:  Christian J Nelson; Chris Diblasio; Muammer Kendirci; Wayne Hellstrom; Patricia Guhring; John P Mulhall
Journal:  J Sex Med       Date:  2008-06-28       Impact factor: 3.802

5.  Untreated duration predicted the severity of depression at the two-year follow-up point.

Authors:  Ching-I Hung; Chia-Yih Liu; Ching-Hui Yang
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

6.  Depression and Suicidality in Gay Men: Implications for Health Care Providers.

Authors:  Carrie Lee; John L Oliffe; Mary T Kelly; Olivier Ferlatte
Journal:  Am J Mens Health       Date:  2017-01-19

Review 7.  The center for epidemiologic studies depression scale: a review with a theoretical and empirical examination of item content and factor structure.

Authors:  R Nicholas Carleton; Michel A Thibodeau; Michelle J N Teale; Patrick G Welch; Murray P Abrams; Thomas Robinson; Gordon J G Asmundson
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

Review 8.  Screening for Depression in the General Population with the Center for Epidemiologic Studies Depression (CES-D): A Systematic Review with Meta-Analysis.

Authors:  Gemma Vilagut; Carlos G Forero; Gabriela Barbaglia; Jordi Alonso
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

9.  Undiagnosed depression: A community diagnosis.

Authors:  Sharifa Z Williams; Grace S Chung; Peter A Muennig
Journal:  SSM Popul Health       Date:  2017-07-28

10.  What about the partner? -factors associated with patient-perceived partner dyspareunia in men with Peyronie's disease.

Authors:  Yifan Meng; David Y Yang; Kevin M Hebert; Josh B Savage; Manaf Alom; Tobias S Kohler; Landon Trost
Journal:  Transl Androl Urol       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.